PortView
Defiance Autism Impact (ASD) ETF Holdings & Analysis
ETFOther
$27.89+0.98%
52-week range$27.89
$24.59$28.52
What ASD does
It operates as an exchange-traded investment fund.
Fund profile
Category
Other
AUM
$1.41M
Holdings
10
52-week high
$28.52
52-week low
$24.59
Top holdings
| Holding | Weight | |
|---|---|---|
| Definium Therapeutics Inc | 3.82% | |
| Neuren Pharmaceuticals Ltd | 3.66% | |
| LifeStance Health Group Inc | 3.50% | |
| Otsuka Holdings Co Ltd | 3.36% | |
| ACADIA Pharmaceuticals Inc | 3.23% | |
| Repligen Corp | 3.05% | |
| Revvity Inc | 2.99% | |
| Bristol-Myers Squibb Co | 2.81% | |
| Life Healthcare Group Holdings Ltd | 2.81% | |
| BioMarin Pharmaceutical Inc | 2.79% |
Geographic allocation
| United States | 55.19% |
| Australia | 3.66% |
| Japan | 11.14% |
| South Africa | 2.81% |
| Sweden | 2.75% |
| United Kingdom | 4.94% |
| France | 2.56% |
| Switzerland | 5.09% |
| Israel | 4.86% |
| Ireland | 2.47% |
PortView Portfolio Insights
PortView analyzes how ASD fits your actual portfolio — position weight, ETF overlap with your other funds, sector and geographic exposure, concentration, and how this fund contributes to your portfolio risk and return. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze ASD in PortView →Related securities
Related stocks
Frequently asked questions
- What does ASD track?
- ASD is the Defiance Autism Impact ETF, a Other ETF.
- What is the expense ratio of ASD?
- Expense ratio data for ASD is shown on the page when available from our data provider.
- What are the largest holdings in ASD?
- Top holdings include DFTX, NEU.AX, LFST, 4578.T, ACAD.
- How can PortView analyze ASD overlap with other ETFs?
- PortView computes the holdings overlap between ASD and the other ETFs and stocks you own, plus your combined sector and geographic exposure, so you can see true diversification.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.